Fraudulent A.I. Company Fools New York Times

TL;DR

Medvy, a two-person 'AI company' hyped by the NYT, is actually a fraudulent telehealth marketer selling illegal compounded GLP-1 drugs through deceptive advertising.

Key Points

• 1.Medvy is an affiliate marketing scheme, not an AI company. It runs paid ads funneling customers to partner compounding pharmacies Care Validate and Open Loop, taking payment without ever possessing or dispensing drugs itself.
• 2.The company's advertising is systematically fraudulent. Medvy used fake AI-generated customer photos, stole a real Reddit user's weight-loss transformation image to invent 'Michael P,' and displayed a real doctor's LinkedIn photo (Dr. Ana Lisa Carr) without her knowledge or employment.
• 3.Medvy's core product is likely illegal. The FDA declared the GLP-1 shortage over in early 2025, making compounded generic versions illegal to sell; Medvy continues selling them anyway and received an FDA warning letter in February 2025.
• 4.The New York Times article was riddled with false claims. The NYT reported $1.8B revenue (actual 2025 revenue: ~$400M), called it a two-person company (reality: 2 founders plus 9 contractors), and ignored Futurism's damning exposé published nearly a year earlier.
• 5.The 'AI unicorn' narrative is undermined by both Medvy and OpenAI itself. Despite Sam Altman claiming one person with AI can do the work of hundreds, OpenAI grew from 4,000 to a planned 8,000 employees in 2026, contradicting the AI-replaces-labor story used to justify massive valuations.